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Introduction {#sec1}
============

Germ cells are the only cells that continue to be reprogrammed throughout their lifetime in order to transfer genetic information to subsequent generations ([@bib36]). Germ cells have unique characteristics such as genome-wide epigenetic reprogramming and the potential to become pluripotent ([@bib35]). Primordial germ cells (PGCs) are specified at embryonic day (E) 7 in the epiblast. *Blimp-1*, *Prdm14*, and *Tfap2c* have critical roles in the specification of PGCs. A functional study of knockout embryos showed that BLIMP-1 represses somatic genes ([@bib29]), whereas PRDM14 activates germ cell development genes ([@bib45]). *Tfap2c* is thought to be a functional downstream target of BLIMP-1 ([@bib44]). These three factors are sufficient to induce PGCs in vitro ([@bib28]). Germ cell development, especially PGC specification, shares similarities with somatic cell reprogramming. Factors involved in germ cell development also function in the reprogramming of somatic cells ([@bib24]). Moreover, PGCs have the potential to dedifferentiate into pluripotent embryonic germ cells (EGCs) without exogenous gene activation ([@bib21]). Although pluripotent stem cells and PGCs share many common features, PGCs are unipotent germ lineage-restricted cells and are distinct from pluripotent stem cells. When injected into blastocysts, PGCs do not give rise to any cell lineages ([@bib16]).

Originally, EGCs were established thorough screening of the culture conditions required for PGC proliferation ([@bib21]). Basic fibroblast growth factor (bFGF), leukemia inhibitory factor (LIF), and membrane-bound stem cell factor (mSCF) are present under these culture conditions. Because activation of phosphoinositide-3-kinase and AKT signaling negates the requirement for bFGF in such cultures, *Akt* is known to be involved in the induction of pluripotency in PGCs ([@bib13]). Recently, it was reported that a combination of signaling inhibitors enhances the efficiency of EGC formation ([@bib15; @bib25]). These inhibitors consist of 2i inhibitors (inhibitors of mitogen-activated protein kinase kinase \[MEK\] and glycogen synthase kinase-β), which maintain pluripotency, and A83 (an inhibitor of transforming growth factor-β receptor), which enhances somatic cell reprogramming ([@bib48; @bib50]). However, the mechanisms underlying the induction of pluripotency in PGCs remain largely elusive. While only germ cells can give rise to pluripotent cells following implantation, induced pluripotent stem cell (iPSC) technology enables pluripotent cells to be established from somatic cells ([@bib40]). Methyl-CpG binding domain protein 3 (Mbd3) was recently identified as a roadblock of somatic cell reprogramming ([@bib34]). MBD3 is a component of the nucleosome remodeling deacetylase (NuRD) complex, which has histone deacetylase activity and serves to close the chromatin structure ([@bib7]).

In this study, we performed extensive gene expression analysis during the dedifferentiation of PGCs into EGCs and combined these data with the data for previously published target gene sets. Extensive analysis of transcription profiles revealed that BLIMP-1 suppressed pluripotency network genes and was therefore a pluripotency gatekeeper protein in PGCs. Moreover, there was a synergistic effect of AKT activation in the presence of bFGF and 2i+A83 on EGC formation. AKT activation suppressed genes regulated by MBD3. The targets of AKT and BLIMP-1 were different. Taken together, these results provide insight into the mechanism by which PGCs are converted into EGCs.

Results {#sec2}
=======

Transcriptome Analysis during the Conversion of PGCs into Pluripotent Stem Cells {#sec2.1}
--------------------------------------------------------------------------------

To elucidate the molecular mechanisms by which PGCs become pluripotent cells, we performed whole-transcriptome analysis during the conversion of PGCs into EGCs. To obtain precise data, we used specific culture conditions for purified pluripotent candidate cells as previously reported ([Figure 1](#fig1){ref-type="fig"}A) ([@bib23]). Heatmap and principal component analysis (PCA) indicated that the acquisition of pluripotency in PGCs is a stepwise process ([Figures 1](#fig1){ref-type="fig"}B and 1C). [Table S1](#mmc2){ref-type="supplementary-material"} shows the various genes that are gradually upregulated and downregulated during the conversion process. Gene Ontology (GO) analysis indicated that the transcription of genes involved in processes such as "transcription, DNA-dependent" and "regulation of transcription, DNA-dependent" was upregulated, while the transcription of genes involved in "protein-chromophore linkage" was downregulated ([Table S1](#mmc2){ref-type="supplementary-material"}). To understand the global changes in gene expression during the acquisition of pluripotency, we compared the numbers of differentially expressed genes at each time point of the culture ([Figure 1](#fig1){ref-type="fig"}D). There were two waves observed by differentially expressed genes. The first wave was from day 0 to day 1, and the second wave was from day 6 to day 10. When these differentially expressed genes were divided into upregulated or downregulated genes, most genes in the first wave were upregulated, and most genes in the second wave were downregulated ([Figure 1](#fig1){ref-type="fig"}E). Moreover, more than half of the genes upregulated in the first wave were downregulated in the second wave ([Figure 1](#fig1){ref-type="fig"}F; [Table S1](#mmc2){ref-type="supplementary-material"}), indicating that they were oppositely regulated during these time periods. When we focused on these genes, GO analysis revealed the enrichment of terms associated with the "cell cycle," "development," and "metabolism" ([Table S1](#mmc2){ref-type="supplementary-material"}).

Next, we analyzed the characteristic gene expression of PGCs. Gene set enrichment analysis (GSEA) showed that PGC markers were downregulated from day 2 of the culture ([Figure 1](#fig1){ref-type="fig"}G). This indicated that the PGC characteristics were lost in the early phase of pluripotency acquisition.

Analysis of the Core Transcription Network Involved in the Conversion of PGCs into Pluripotent Stem Cells {#sec2.2}
---------------------------------------------------------------------------------------------------------

To analyze gene expression in pluripotent candidate cells ([@bib25]), we focused on downstream targets of the core transcription network ([@bib11]). Because PGCs express key transcription factors of pluripotent stem cells, such as *Oct3/4*, *Sox2*, and *Nanog* ([@bib27]), it would be difficult to understand the differences between pluripotent stem cells and PGCs from the expression of these key factors themselves. In fact, with the exception of *Dax1*, the expression levels of the key pluripotency core network did not fluctuate during the acquisition of pluripotency ([Figure S1](#mmc1){ref-type="supplementary-material"}). Therefore, we focused on the gene expression changes in the downstream targets of the core transcription network. We collected target gene sets from previous reports and applied these data to the GSEA of our time course gene expression profiles ([Figure 2](#fig2){ref-type="fig"}A) ([@bib11]). Whereas the target genes of OCT3/4 tended to be repressed until EGCs formed, the targets of other core network factors were maintained or gradually upregulated during the conversion of PGCs into EGCs ([Figure 2](#fig2){ref-type="fig"}A). To evaluate the changes of this network, we calculated the numbers of genes commonly regulated by various network factors ([Figure 2](#fig2){ref-type="fig"}B). Some of these commonly regulated genes were involved in the process of pluripotency acquisition. Genes regulated by multiple factors of the core network are generally active in embryonic stem cells (ESCs), and these factors may be important in self-renewal and lineage commitment ([@bib11; @bib9]). Therefore, we focused on genes that shared more than seven of nine regulatory factors in common ([Table S2](#mmc1){ref-type="supplementary-material"}). Most of these genes that were activated in the early stage of the culture were also implicated in the late stage. Seven of ten genes involved in both the early (before day 3) and late (after day 6) culture stages encoded DNA-binding proteins involved in the control of transcription and/or chromatin remodeling (*Klf9*, *Dido1*, *Rarg*, *Trim8*, *Mybl2*, *Zfp207*, and *Chd9*). Such factors might function as a hub for the gene expression of other components of the core network.

The PGC-Specific Gene Blimp-1 Represses Downstream Targets of Pluripotency Network Genes {#sec2.3}
----------------------------------------------------------------------------------------

Microarray data of the conversion of PGCs into EGCs revealed an inverse correlation between certain PGC characteristics and pluripotent characteristics. We speculated that there is a mechanism that suppresses pluripotent characteristics in PGCs. To investigate this possibility, we performed microarray analysis of ESCs, which expressed each germ gene. First, we selected six genes that are preferentially expressed in PGCs rather than in ESCs, namely, *Prdm14*, *Vasa*, *Nanos2*, *Nanos3*, *Dnd*, and *Blimp-1* ([Figure 3](#fig3){ref-type="fig"}A) ([@bib45; @bib41; @bib38; @bib39; @bib49; @bib29]). We generated ESCs that expressed PGC genes under the control of doxycycline ([@bib20]). We could not obtain a stable clone of inducible *Blimp-1*-expressing ESCs; therefore, *Blimp-1*-overexpressing cells were analyzed by transfection of ESCs with the *Blimp-1-IRES-AcGFP* vector and sorting of GFP-positive cells by fluorescence-activated cell sorting (FACS). Gene expression levels were confirmed by RT-PCR ([Figure 3](#fig3){ref-type="fig"}B). Microarray data were integrated with previously reported pluripotency network targets as shown in [Figure 2](#fig2){ref-type="fig"}A. *Prdm14* is essential for germ cell specification and the maintenance of ESC pluripotency ([@bib46]). When *Prdm14* was overexpressed in ESCs, downstream targets of the pluripotency network were activated ([Figure 3](#fig3){ref-type="fig"}C). Similarly, expression of the other four germ cell-specific genes (*Vasa*, *Nanos2*, *Nanos3*, and *Dnd*) activated these downstream targets ([Figure 3](#fig3){ref-type="fig"}C). However, when *Blimp-1* was overexpressed in ESCs, the downstream targets were clearly repressed ([Figure 3](#fig3){ref-type="fig"}C). These results suggest that pluripotency suppression is not achieved by the cooperation of multiple germ cell factors; rather, *Blimp-1* appears to function as a pluripotency gatekeeper protein in PGCs.

Identification of a Blimp-1 Module in ESCs {#sec2.4}
------------------------------------------

To understand the mechanism by which BLIMP-1 suppresses downstream targets of the pluripotency network, we attempted to identify BLIMP-1 targets in ESCs. Recently, BLIMP-1-regulated genes were identified by chromatin immunoprecipitation (ChIP)-sequencing analysis of BLIMP-1 in PC19 pluripotent embryonic carcinoma cells ([@bib18]). These BLIMP-1-regulated genes were projected to pluripotency controlling modules of CoORE, Polycomb (PRC), and MYC ([@bib12]). In total, 4,808 unique genes were identified from BLIMP-1 ChIP-sequencing analysis and were included in the modules. We referred to these putative BLIMP-1 targets in ESCs as the BLIMP-1 modules ([Figure 4](#fig4){ref-type="fig"}A). Among the CORE, PRC, and MYC modules, about 40% of genes belonged to the BLIMP-1 module ([Figures 4](#fig4){ref-type="fig"}B and 4C). Next, the BLIMP-1 module was applied to our microarray data from *Blimp-1*-overexpressing ESCs. When *Blimp-1* was overexpressed in ESCs, the majority of BLIMP-1 module genes were downregulated, while about 10% of genes were upregulated ([Figure 4](#fig4){ref-type="fig"}D). Most of these upregulated genes were collectively classified as a PRC module ([Figures 4](#fig4){ref-type="fig"}E--4G). In ESCs, whereas CORE and MYC modules are activated, PRC modules are suppressed ([@bib12]). Therefore, *Blimp-1* likely suppressed pluripotency through a BLIMP-1 module.

Blimp-1 Depletion Induces Pluripotency in PGCs {#sec2.5}
----------------------------------------------

To clarify the functional role of *Blimp-1* in pluripotency acquisition in PGCs, we deleted *Blimp-1*. First, we purified PGCs from *Blimp-1*-floxed mouse embryos and then used recombinant CRE protein to delete *Blimp-1* ([@bib29]). CRE-treated PGCs were seeded onto STO or m220 feeder cells without bFGF. In the absence of bFGF, PGCs could not convert to EGCs ([@bib4]). m220 feeder cells express mSCF, which is an important signal for EGC formation ([@bib21]). After culture, ESC-like colonies formed from *Blimp-1*-deleted PGCs grown on both types of feeder cells ([Figures 5](#fig5){ref-type="fig"}A--5C). *Blimp-1* deletion was confirmed by genomic PCR ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Additional treatment with 2i+A83, which enhances EGC generation ([@bib25]), also enhanced the efficiency with *Blimp-1* deletion. On the other hand, in the presence of bFGF, the efficiency was decreased. These results indicated that there is no synergistic effect between *Blimp-1* deletion and bFGF. The gene expression pattern in *Blimp-1*-deleted ESC-like colony cells indicated that the lack of *Blimp-1* induced the upregulation of *Klf4* and *ERas* ([Figure 5](#fig5){ref-type="fig"}D). When injected into nude mice, these established ESC-like cells formed teratomas containing three germ layers ([Figures 5](#fig5){ref-type="fig"}E and 5F), reminiscent of pluripotent stem cells. These results indicate that *Blimp-1* deletion causes PGCs to becoming pluripotent. In the next experiment, rather than deleting *Blimp-1*, we induced the forced expression of *Blimp-1* in PGCLCs during EGC formation. PGCLCs are in vitro-induced PGCs from ESCs ([@bib6]). In this study, we established these cells using doxycycline inducible *Blimp-1*-expressing ESCs ([@bib28]). When *Blimp-1* was induced at the early phase of the EGC formation, PGCLCs could not convert to EGCs ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To confirm the effect of BLIMP-1 modules during the acquisition of pluripotency in PGCs, we analyzed expression changes of BLIMP-1 modules in the time course transcriptome data. Whereas the BLIMP-1 modules of CORE and MYC were activated, the BLIMP-1 module of PRC was suppressed ([Figure 5](#fig5){ref-type="fig"}G). These changes correspond to the regulation in ESCs, suggesting that the BLIMP-1 modules are of functional relevance during EGC formation ([@bib12]). Taken together, these results show that *Blimp-1* acted as a gatekeeper of pluripotency in PGCs.

AKT Has a Synergistic Effect with bFGF and 2i+A83 on the Acquisition of Pluripotency {#sec2.6}
------------------------------------------------------------------------------------

Next, we analyzed the key signaling required for the acquisition of pluripotency in PGCs. Whereas bFGF is an essential signal for the generation of EGCs from PGCs ([@bib4]), AKT activation has been reported to be sufficient to induce EGCs ([@bib13]). To analyze the effect of AKT activation, we used PGCs from *Akt-mer* Tg mice ([@bib13]). In these mice, AKT is activated by adding 4OHT. We found that AKT activation induced EGCs from PGCs in the absence of bFGF ([Figure 6](#fig6){ref-type="fig"}A). To analyze the AKT signal, we collected AKT target molecules in ESCs from a previous report ([@bib47]). When the expression profiles of AKT targets were applied to our time course gene expression data, the AKT targets were shown to be activated from day 1 of the culture ([Figure 6](#fig6){ref-type="fig"}B). These results indicated that the AKT targets were activated during pluripotency acquisition. Next, we analyzed AKT and other target genes. In the BLIMP-1modules, the AKT targets did not largely overlap (overlap was highest in the BLIMP-1 PRC module, at 11.11%) ([Figure 6](#fig6){ref-type="fig"}C). In addition, all BLIMP-1 targets shared few targets with AKT ([Figure 6](#fig6){ref-type="fig"}D). Moreover, all ESC modules shared a few common targets with AKT ([Figure 6](#fig6){ref-type="fig"}E), suggesting that the effect of AKT activation on the dedifferentiation of PGCs is independent of BLIMP-1 targets or ESC modules. On the other hand, AKT activation is known to enhance the formation of EGCs from PGCs in the presence of bFGF ([@bib13]). In addition, although AKT activation induced EGCs in the absence of bFGF in the present study, 2i+A83 treatment enhanced the efficiency of this process ([Figure 6](#fig6){ref-type="fig"}A). We speculated that AKT has additive or synergistic effects with bFGF and/or 2i+A83. Therefore, we analyzed the combinatorial effect of bFGF, 2i+A83, and AKT activation. We found that AKT activation strongly enhanced EGC formation in the presence of bFGF and 2i+A83 ([Figure 6](#fig6){ref-type="fig"}F). Thus, AKT activation, bFGF, and 2i+A83 have a synergistic effect on the acquisition of pluripotency in PGCs. This combination of signals allowed us to generate EGCs even in the absence of feeder cells, serum, and serum replacement (KSR) ([Figure 6](#fig6){ref-type="fig"}G).

AKT Enhances the Acquisition of Pluripotency by Suppressing Mbd3 {#sec2.7}
----------------------------------------------------------------

To understand how AKT signaling enhanced the acquisition of pluripotency in PGCs, we performed a whole-transcriptome analysis of cells subjected to each combination of treatments ([Figure 7](#fig7){ref-type="fig"}A). Inactivation of *Mbd3* was recently reported to greatly enhance the efficiency of reprogramming ([@bib34]). This previous study identified the target genes of MBD3 by ChIP sequencing in untreated mouse embryonic fibroblasts (MEFs) and those transduced with four reprogramming factors (*Oct3/4*, *Sox2*, *Klf4*, and *c-Myc*, hereafter referred to as OSKM). We analyzed the expression profiles of these MBD3 target genes in the microarray data ([Figure 7](#fig7){ref-type="fig"}B). The heatmap results clearly showed that AKT signaling suppressed the MBD3 targets of OSKM-transduced MEFs. This tendency was also observed for the MBD3 targets of untreated MEFs ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). To understand the function of the MBD3 targets of OSKM-transduced MEFs in PGCs, we analyzed the overlap between MBD3 targets and BLIMP-1 target genes. MBD3 targets in OSKM-transduced MEFs shared few targets with the BLIMP-1 modules or with all BLIMP-1 targets ([Figures 7](#fig7){ref-type="fig"}C and 7D). In addition, the ESC modules did not overlap with the MBD3 targets of OSKM-transduced MEFs ([Figure 7](#fig7){ref-type="fig"}E). Moreover, when looking at the microarray data of PGCs subjected to various treatments, we found that AKT activation was not correlated with the changes in BLIMP-1 modules that accompanied EGC generation, namely, activation of the Core and Myc modules and suppression of the PRC module ([Figure 7](#fig7){ref-type="fig"}F). Taken together, these findings showed that AKT activation suppressed the MBD3 targets of OSKM-transduced MEFs in PGCs, which were different from the downstream targets of the BLIMP-1 and ESC modules. Finally, we analyzed whether AKT activation also downregulates MBD3 during somatic cell reprogramming. We found that, following the activation of AKT, MBD3 expression was suppressed in MEFs ([Figures 7](#fig7){ref-type="fig"}F and [S3](#mmc1){ref-type="supplementary-material"}E). Furthermore, AKT activation at the early phase of somatic cell reprogramming enhanced the efficiency of this process ([Figure 7](#fig7){ref-type="fig"}H). Therefore, AKT activation enhanced pluripotency acquisition in MEFs via the suppression of MBD3-regulated genes.

Discussion {#sec3}
==========

We have identified that Blimp-1 functions as a gatekeeper of pluripotency in PGCs. *Blimp-1* was originally identified as a transcriptional repressor in B cell maturation ([@bib42]). During PGC specification, BLIMP-1 is important for the suppression of somatic cell programming ([@bib14]). The targets of BLIMP-1 may differ according to the situation. Transcription factors change the targets in a cell state-dependent manner. For example, Niwa et al. reported that the targets of SOX2 differed between ESCs and trophoblast stem cells because of different binding partners ([@bib1]). It is reported that BLIMP-1 binds the histone deacetylases TLE1 and EHMT2 in a context-dependent manner ([@bib2]). It would be interesting to analyze the binding partners of BLIMP-1 during the specification of PGCs and induction of EGCs.

Whereas we found that *Blimp-1* deletion induced pluripotency in PGCs, the effects of *Blimp-1* overexpression in pluripotent cells appear to be more complicated. Forced expression of *Blimp-1* in ESCs induces growth retardation ([@bib24]). During PGC induction from ESCs, induction of an intermediate cell state, namely epiblast-like cells (EpiLCs), is important ([@bib6]). The combination of transcription factors *Prdm14*, *Blimp-1*, and *Tfap2c* is critical to induce PGCs from EpiLCs ([@bib28]). However, forced induction of these three factors cannot induce PGCs directly from ESCs. Furthermore, whereas *Prdm14* alone can induce PGCs with low efficiency, *Blimp-1* alone cannot even induce PGCs from EpiLCs. Overexpression of *Prdm14* in ESCs enhances pluripotency maintenance but does not induce PGC differentiation ([@bib31]). These facts reveal that there are important differences between ESCs and EpiLCs in relation to PGC induction. One such difference is the existence of a suppressive mechanism in ESCs. Recently, it was reported that inactivation of *Myc* induces upregulation of germ cell marker genes in ESCs ([@bib17]). This indicates that PGC induction is suppressed in ESCs. However, in that report, *Vasa* was expressed much earlier than in vivo, and early markers, such as *Blimp-1*, were not activated efficiently. Therefore, it is unclear whether *Myc* inactivation induces functional differentiation. It would be intriguing to analyze differences between ESCs and EpiLCs in relation to the prerequisites for PGC differentiation.

To our surprise, overexpression of *Dnd* enhanced downstream targets of pluripotency ([Figure 3](#fig3){ref-type="fig"}). When *Dnd* is inactivated, the number of PGCs is decreased but basal PGCs give rise to teratomas in vivo ([@bib49]). Teratomas contain three germ layers generated by pluripotent cells. Therefore, deletion of *Dnd* leads to pluripotency in PGCs. However, in the present work, *Dnd* did not appear to mediate the suppression of pluripotency in ESCs. *Dnd* is not a target gene of either BLIMP-1 or AKT ([Dataset S1](#mmc3){ref-type="supplementary-material"}), indicating that *Dnd* is regulated differently from BLIMP-1 or AKT. The mechanisms underlying pluripotency acquisition upon *Dnd* deletion, and the relationship between *Dnd* and *Blimp-1* or *Akt* in PGCs is an important issue to be investigated.

In this study, we found a synergistic effect of AKT activation in the presence of bFGF and 2i+A83 on the acquisition of pluripotency. AKT activation suppressed MBD3-regulated genes in PGCs ([Figure 7](#fig7){ref-type="fig"}B). Furthermore, AKT activation downregulated MBD3 in MEFs ([Figure 7](#fig7){ref-type="fig"}G). Both AKT activation and MBD3 inactivation have been shown to prevent differentiation of ESCs in the absence of LIF ([@bib43; @bib10]). It is conceivable that AKT downregulates MBD3 and thereby maintains pluripotency in the absence of LIF. *Mbd3* is a roadblock of pluripotency ([@bib34]). However, the regulation of *Mbd3* expression is poorly understood. It would be interesting to analyze how AKT signaling downregulates *Mbd3*.

It has been reported that a histone deacetylase (HDAC) inhibitor had a positive effect on EGC formation. We therefore analyzed AKT activation and HDAC target genes. For this purpose, we determined the genes that were upregulated in *Hdac*-deficient ESCs ([@bib8]). GSEA analysis was performed at day 2 of the culture with or without AKT activation ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Whereas bFGF alone activated HDAC target genes, AKT activation suppressed this gene set, indicating that AKT enhances the formation of EGCs in a manner distinct from that of the HDAC pathway.

In this study, we used target gene set analysis. We considered that this approach would allow us to understand the gene network and epigenetic state, which are difficult to analyze based on the individual gene expressions. Whereas both PGCs and EGCs express *Oct3/4*, the downstream targets of OCT3/4 were repressed from days 1 to 10 ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}A). This indicated that the region downstream of OCT3/4 might differ between PGCs and EGCs. It was previously shown that *Oct3/4* plays a critical role in PGC specification ([@bib30]). It would thus be of interest to investigate the molecular interaction between *Oct3/4* and the factors that are important for PGC specification, such as *Blimp-1* and *Prdm14*. We also applied this approach to epigenetic modifications. First, we analyzed the histone modification-associated active genes (H3K36me3, H3K79me2, and H3K4me3) ([@bib19; @bib22]). The targets of these modifications were also gradually upregulated ([Figure S1](#mmc1){ref-type="supplementary-material"}B). On the other hand, another set of modification targets consisting of H3K4me3, H3K27me3, or both (i.e., the Bivalent domain targets) showed intriguing change ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Whereas the targets of the Bivalent domain were upregulated in EGCs compared with early culture periods, the H3K27me3 targets were repressed. The targets of H3K4me3 were maintained in an active state. With respect to the targets of DNA methylation, three different gene sets of 5hmC and two different gene sets of 5meC were collected from three different papers ([@bib32; @bib3; @bib5]). Except for one time point (EGCs of [Figure S1](#mmc1){ref-type="supplementary-material"}E), both the 5hmC and 5mC targets were activated from the early phase of the culture ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F). PGCs contain DNA with a low level of methylation ([@bib37]). Therefore, it is feasible that the targets of DNA methylation in ESCs are already hypomethylated in PGCs and so easy for the early activation.

To understand how pluripotency is achieved, we compared somatic cell reprogramming with the acquisition of pluripotency in PGCs. Although these two phenomena are different, the obtained pluripotent stem cells have similar characteristics. Analysis of how pluripotent stem cells are generated from different cell types might help to clarify the mechanism of reprogramming. Of note, PGCs already have many similarities with pluripotent stem cells. Both processes showed two distinct waves of gene expression changes, in the early and late phases ([@bib33]). During somatic cell reprogramming, both waves showed similar patterns of upregulated and downregulated genes. In contrast, during the acquisition of pluripotency in PGCs, the first and second waves were mainly composed of upregulated and downregulated genes, respectively ([Figure 1](#fig1){ref-type="fig"}E). These oppositely regulated genes are associated with the GO terms cell cycle, development, and metabolism ([Table S1](#mmc2){ref-type="supplementary-material"}). In the early phase of somatic cell reprogramming, genes associated with "gain of proliferation", "transient activation of developmental regulators", and "metabolic changes" are regulated ([@bib33]). Genes that are oppositely regulated during the conversion of PGCs to EGCs might have an important role in somatic cell reprogramming. Furthermore, in both cases, cells lost their original characteristics during the early phase, after which genes in the pluripotency-associated network were upregulated. Comparison of these two types of pluripotency induction would improve our understanding of the reprogramming mechanisms and characteristics of PGCs. Taken together with the results of our previous study ([@bib25]), these findings summarize the process of acquisition of pluripotency in PGCs ([Figure 7](#fig7){ref-type="fig"}I).

This study presents precise information on gene expression profiles during the acquisition of pluripotency in PGCs. This information, in turn, provides mechanistic insights into the difference between PGCs and pluripotent stem cells and can be used to investigate the mechanism underlying somatic cell reprogramming. In future studies, it would be useful to compare distinct cell types and mechanisms to better understand the germ cell characteristics and reprogramming machinery.

Experimental Procedures {#sec4}
=======================

Isolation and Culture of PGCs {#sec4.1}
-----------------------------

PGCs were purified and cultured as described previously ([@bib23]), and the detail is described in the [Supplemental Information](#app3){ref-type="sec"}.

Microarray Analysis {#sec4.2}
-------------------

Microarray analysis was performed using Whole Mouse Genome Oligo Microarray 44K (Agilent Technologies), and the detailed information is described in the [Supplemental Information](#app3){ref-type="sec"}.

Generation and Isolation of ESCs Expressing Germ Cell Genes {#sec4.3}
-----------------------------------------------------------

Germ cell factors were introduced into EBRTcH3 ESCs as described in a previous report ([@bib20]), and the detail is described in the [Supplemental Information](#app3){ref-type="sec"}.

Teratoma Formation and Alkaline Phosphatase Staining {#sec4.4}
----------------------------------------------------

Teratoma formation and alkaline phosphatase staining were performed as described previously ([@bib25]), and the detail is described in the [Supplemental Information](#app3){ref-type="sec"}.

Antibodies {#sec4.5}
----------

The monoclonal antibodies used for western blotting were rabbit anti-MBD3 (ab157464; Abcam) and rabbit anti-β-ACTIN (A-2066; Sigma).

iPSC Generation {#sec4.6}
---------------

AKT-mer MEFs were reprogrammed using *Oct3/4*, *Sox2*, and *Klf4* as described previously ([@bib26]). 4OHT was added at day 2 and allowed to react to day 6 after the three-factor induction. The numbers of morphologically ESC-like colonies were counted at day 22.

Author Contributions {#sec5}
====================

G.N., K.T., and T.S. designed the project. G.N. performed the experiments and generated the figures. S.S. performed bioinformatics analysis, and G.N. and T.S. wrote the manuscript.

Accession Numbers {#app1}
=================
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Document S1. Supplemental Experimental Procedures, Figures S1--S3, and Table S2Table S1. Detailed Information about Time Course Microarray Analysis from E11.5 PGCs to EGCsDataset S1. Lists of the Target GenesDocument S2. Article plus Supplemental Information

We thank Dr. A. Tarakhovsky (Rockefeller University) for providing the Blimp-1^flox/flox^ mice and Dr. T. Nakano and Dr. T. Kimura (Osaka University) for providing the AKT-Mer mice. We also thank Dr. K. Hosokawa (Kyushu University) for providing the recombinant CRE protein and Dr. K. Hayashi (Kyushu University) for a critical reading of this manuscript. This study was supported in part by a grant from the Project for Realization of Regenerative Medicine. Support for the Core Institutes for iPS Cell Research was provided by MEXT and the Keio University Medical Science Fund. G.N. was supported by a PRESTO grant of the Japan Science and Technology Agency and by Funds for the Development of Human Resources in Science and Technology of the Program to Disseminate a Tenure Tracking System for the Tenure-Track Program at the Sakaguchi Laboratory.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Supplemental Information includes Supplemental Experimental Procedures, three figures, two tables, and one dataset and can be found with this article online at [http://dx.doi.org/10.1016/j.stemcr.2015.05.007](10.1016/j.stemcr.2015.05.007){#intref0015}.

![Microarray Analysis of the Acquisition of Pluripotency in PGCs\
(A) Summary of the procedure used to culture cells and isolate samples. Gonads were surgically isolated from E11.5 embryos. After making a single cell suspension, PGCs were isolated based on SSEA-1 expression using a FACS AriaII cell sorter. Purified PGCs were seeded onto m220 feeder cells in ESC medium containing bFGF. One day after seeding, 2i+A83 was added to the culture. At day 3 of culture, the cells were reseeded onto STO feeder cells. At day 7 of culture, bFGF and 2i+A83 were removed by changing the medium. Colonies were picked, and EGC lines were established. At each time point, pluripotent candidate cells were sorted based on stage-specific embryonic antigen-1 (SSEA-1) expression for microarray analysis ([@bib23]). 2i+A83 was composed of inhibitors of MEK (PD325901), glycogen synthase kinase-β (CHIR99021), and transforming growth factor-β type 1R (A83-01).\
(B) Array heatmap of differentially expressed genes according to the culture period.\
(C) Principle component analysis during the acquisition of pluripotency in PGCs.\
(D) The number of differentially expressed genes at each adjacent time point.\
(E) The numbers of upregulated and downregulated genes at each adjacent time point.\
(F) The numbers of oppositely regulated genes at day 0 versus day 1 and day 6 versus day 10 during the acquisition of pluripotency. The bars indicate the total number of genes at each time point. Red indicates common genes at day 0 versus day 1 or day 6 versus day 10. The percentage of common genes is shown below each bar. DN, downregulated; UP, upregulated.\
(G) GSEA of the PGC markers.\
See also [Table S1](#mmc2){ref-type="supplementary-material"}.](gr1){#fig1}

![GSEA of Downstream Targets\
(A) GSEA of downstream targets of the pluripotency network from [@bib11].\
(B) The numbers of involved genes (blue), genes shared with a previous time point (green), and common genes (red) of the GSEA.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Blimp-1 Represses Downstream Targets of Pluripotency Network Genes\
(A) Gene expression of the germ cell markers is shown. Expression in E11.5 PGCs was compared with that in ESCs (TT2). Relative gene expression is shown (mean ± SD; independent experiments, n = 3). Red bars indicate the expression level in ESCs (set at 1).\
(B) Gene expression of germ cell markers in ESCs. The expression in overexpressing ESCs was compared with that in parental ESCs. Relative gene expression is shown (mean ± SD; independent experiments, n = 3). Red bars indicate the expression level in parental ESCs (set at 1). In the case of *Blimp-1*, expression in ESCs transfected with *Blimp-1-IRES-AcGFP* was compared with that in ESCs transfected with *IRES-AcGFP*. Red bars indicate the expression level in ESCs transfected with *IRES-AcGFP* (set at 1).\
(C) GSEA of downstream targets of the pluripotency network from [@bib11]. ESCs overexpressing each germ cell gene were compared with parental ESCs. In the case of *Blimp-1*, ESCs were transfected with *pEF1a-IRES-AcGFP* or *EF1a-Blimp-1-IRES-AcGFP*, and then AcGFP-positive cells were sorted and compared.](gr3){#fig3}

![Identification of Blimp-1 Modules in ESCs\
(A) Summary of the identification of BLIMP-1 modules in ESCs. BLIMP-1 targets were obtained from the ChIP-sequencing data of [@bib18] (right). The 4808 BLIMP-1-regulated genes targets were projected to each regulated module of ESCs reported by [@bib12] (left). These overlapped genes were identified as individual BLIMP-1 modules.\
(B) The numbers of BLIMP-1 target genes in each regulated module of ESCs.\
(C) Percentage of BLIMP-1 target genes in each regulated module of ESCs.\
(D) Percentage of upregulated and downregulated BLIMP-1 targets in ESCs at day 2.\
(E) Numbers of upregulated genes in each BLIMP-1 module in *Blimp-1*-overexpressing ESCs at day 2.\
(F) Numbers of downregulated genes in each BLIMP-1 module in Blimp-1-overexpressing ESCs at day 2.\
(G) Percentage of upregulated and downregulated genes in each BLIMP-1 module in *Blimp-1*-overexpressing ESCs at day 2. DN, downregulated; UP, upregulated.](gr4){#fig4}

![Blimp-1 Depletion Induces Pluripotency in PGCs\
(A) Typical morphology of embryonic stem cell (ESC)-like colonies after *Blimp-1* depletion by CRE treatment and culture on feeder cells (m220 or STO). A primary colony at day 10 of culture and an established line are shown. Scale bars 100 μM (top) and 500 μM (bottom).\
(B and C) The number of ESC-like colonies observed 10 days after *Blimp-1* deletion by CRE treatment and culture on m220 (B) or STO (C) feeder cells with or without 2i+A83 treatment. Data represent the mean ± SD of independent experiment. Statistical significance was determined using Tukey's multiple comparison test (n = 5 for no treatment on m220, n = 4 for 2i+A83 on m220, n = 5 for bFGF + 2i+A83, n = 10 for no treatment on STO and n = 4 for 2i+A83 on STO). ^∗∗^p \< 0.01, ^∗^p = 0.019.\
(D) Gene expression analyses of *Blimp-1*-depleted EGCs for *Blimp-1* (left), *Klf4* (middle), and *ERas* (right) are shown (mean ± SD; independent experiments, n = 3).\
(E and F) Teratoma formation by *Blimp-1*-depleted EGCs induced on m220 (E) or STO (F) feeder cells, with or without 2i+A83 treatment. Scale bars represent 50 μM.\
(G) GSEA of BLIMP-1 targets for the microarray time course data. BLIMP-1 modules are the gene sets identified in [Figure 4](#fig4){ref-type="fig"}. rCRE, recombinant CRE.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

![Synergistic Effect of AKT Activation Together with bFGF and 2i+A83 Treatment\
(A) E11.5 PGCs were purified based on SSEA-1 expression. PGCs were seeded onto STO feeder cells in ESC medium containing 4-hydroxytamoxifen (4OHT) with or without 2i+A83. The numbers of ESC-like colonies at day 10 are shown. Data represent the mean ± SD of independent experiments. Statistical significance was determined using Student's t test (n = 3). ^∗^p = 0.047.\
(B) GSEA of AKT targets for the microarray time course data. AKT targets were identified by comparison with the data of [@bib47].\
(C) Number of AKT targets in Blimp-1 modules. The bars indicate the total number of genes in each Blimp-1 module ([Figure 4](#fig4){ref-type="fig"}A). Red indicates AKT target genes.\
(D) Number of AKT targets among all BLIMP-1 targets ([@bib18]).\
(E) Number of AKT targets in regulated modules of ESCs ([@bib12]).\
(F) The number of colonies at day 10 of the culture (top) and alkaline phosphatase (ALP) staining (bottom) are shown. Scale bar represents 7 mM (top). E11.5 PGCs were collected from AKT-Mer embryos based on SSEA-1 expression and induced to undergo conversion into EGCs by culture in ESC medium containing the specified chemicals. Data represent the mean ± SD of independent experiments. Statistical significance was determined using Tukey's multiple comparison test (n = 3). ^∗∗^p \< 0.01.\
(G) (Left) Typical morphology of ESC-like colonies derived from AKT-Mer PGCs at day 8. SSEA-1-positive PGCs were cultured in N2B27 medium containing bFGF, 4OHT, and 2i or 2i+A83 without feeder cells or serum replacement (KSR). The lower panels are higher magnification images of the upper panels. Scale bars represent 250 μM (top) and 100 μM (bottom). (Right) The number of colonies at day 8. Data represent the mean ± SD of independent experiments. Statistical significance was determined using Student's t test (n = 4). ^∗^p = 0.088.](gr6){#fig6}

![AKT Activation Suppresses Mbd3\
(A--F) Summary of the procedure used to culture cells and isolate samples for microarray analysis (B--F). Gonads were surgically isolated from E11.5 AKT-mer embryos. After making a single cell suspension, PGCs were isolated based on SSEA-1 expression using a FACS AriaII cell sorter. Purified PGCs were seeded onto m220 feeder cells in ESC medium containing bFGF. One day after seeding, the indicated chemicals were added. On day 2, pluripotent candidate cells were sorted based on SSEA-1 expression for microarray analysis ([@bib23]). 2i comprised inhibitors of MEK and glycogen synthase kinase-β (GSK3-β). A83 indicates the transforming growth factor-β (TGF-β) type 1R inhibitor. (B) Array heatmap analysis for pluripotent candidate cells at day 2 of each treatment. Mbd3 and Mbd3 targets of MEFs in which four reprogramming factors (*Oct3/4*, *Sox2*, *Klf4*, and *c-Myc* \[OSKM\]) were transduced are shown. These target genes are from [@bib34]. (C) The number of MBD3 targets of OSKM-transduced MEFs in BLIMP-1 modules. Bars indicate the total number of genes in each BLIMP-1 module ([Figure 4](#fig4){ref-type="fig"}A). Red indicates MBD3 target genes of OSKM-transduced MEFs. (D) Number of MBD3 targets of OSKM-transduced MEFs among all BLIMP-1 targets ([@bib18]). (E) Number of MBD3 targets of OSKM-transduced MEFs in ESC module ([@bib12]). Bars indicate the total number of genes in each regulated module of ESCs. Red indicates MBD3 target genes of OSKM-transduced MEFs. (F) GSEA of BLIMP-1 targets for pluripotent candidate cells at day 2 of each treatment. BLIMP-1 modules were the gene sets identified in [Figure 4](#fig4){ref-type="fig"}.\
(G) Western blotting of MBD3 after 4-hydroxytamoxifen (4OHT) treatment of MEFs isolated from WT and *Akt-mer* embryos. MEFs were treated with 4OHT (100 nM). At the indicated time points, MEFs were harvested and MBD3 expression was analyzed by western blot.\
(H) The number of 3F (*Oct3/4*, *Sox2* and *Klf4*)-induced ESC-like colonies formed from *Akt-mer* MEFs, with or without 4OHT treatment at day 22. 4OHT was added at day 2 and allowed to react until day 6 after the 3F induction. Data represent the mean ± SD of independent experiments. Statistical significance was determined using Student's t test (n = 6). ^∗∗^p \< 0.01.\
(I) Gene expression regulation of cellular dynamics in the process of the acquisition of pluripotency in PGCs. Events identified in both the current study and a previous study ([@bib25]) are shown. The efficient dedifferentiation of *Mbd3* deficient PGCs was previously reported ([@bib34]).\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
